Article
How I treat acute myeloid leukemia in the era of new drugs.
Blood - 9 Jan 2020
DiNardo Courtney D, Wei Andrew H
Abstract excerpt
The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and...
Topics
- Adult
- Aged
- Aminopyridines
- Aniline Compounds
- Antineoplastic Agents
- Biomarkers, Tumor
- Bridged Bicyclo Compounds, Heterocyclic
- Cytarabine
- Daunorubicin
- Female
- Glycine
- Humans
- Isocitrate Dehydrogenase
- Leukemia, Myeloid, Acute
- Male
- Molecular Targeted Therapy
- Mutation
- Prognosis